Increased prolactin levels during reserpine treatment of hypertensive patients.
Serum prolactin levels are significantly greater among hypertensive patients receiving reserpine as compared to levels six weeks after discontinuing the treatment (P less than .005). This association between regular, long-term reserpine use and greater prolactin levels may be clinically significant, since an increased incidence of breast cancer has been reported among hypertensive patients receiving reserpine.
D000735:Androstenedione / Q000097:blood; D003687:Dehydroepiandrosterone / Q000097:blood; D004958:Estradiol / Q000097:blood; D004970:Estrone / Q000097:blood; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D011388:Prolactin / Q000097:blood*; D012110:Reserpine / Q000494:pharmacology* / Q000627:therapeutic use; D013268:Stimulation, Chemical; D013997:Time Factors
D004970:Estrone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D004958:Estradiol; D012110:Reserpine; D011388:Prolactin; D013006:Growth Hormone